Therapeutic potential of targeting LAG-3 in cancer by Diwakar Davar, Ana Carrizosa Anderson, Ivan Diaz-Padilla

Get full text

First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors by David Turner, Antoine Italiano, Victor Moreno, Steven Hirschfeld, Juan Martin-Liberal, Michele Maio, Todd M Bauer, Christophe Le Tourneau, Danny Rischin, Catherine Ellis, Eric Angevin, Aaron Hansen, Helen Zhou, Ivan Diaz-Padilla, Frans Opdam, Sapna Yadavilli, Marc Ballas

Get full text

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours by J. Randolph Hecht, Jean-Marie Michot, David Bajor, Amita Patnaik, Ki Y. Chung, Judy Wang, Gerald Falchook, James M. Cleary, Richard Kim, Anuradha Krishnamurthy, Omkar Marathe, Hagop Youssoufian, Catherine Ellis, Angela Waszak, Srimoyee Ghosh, Hailei Zhang, Kaitlin Yablonski, Shruti D. Shah, Ivan Diaz-Padilla, Susanna Ulahannan

Get full text

Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols by Deborah Collyar, Christian M Capitini, Gary Kohanbash, Yana G Najjar, Carlo B Bifulco, Barbara Seliger, Holden T Maecker, Elizabeth Garrett-Mayer, Joe Yeong, Leslie Cope, Sacha Gnjatic, Sumit K Subudhi, Michael T Lotze, Saman Maleki Vareki, Alaa Ali, Laura Q M Chow, Tricia R Cottrell, Tullia C Bruno, Denise Goh, Codruta Chiuzan, Janis Taube, Ryan J Sullivan, Kristin G Anderson, Isabella C Glitza Oliva, Wim Vos, Paola Grandi, Susan Halabi, Julie Stein Deutsch, Ivan Diaz-Padilla, Anthony R Cillo, Genia Dubrovsky, Sarah Mullin, Elizabeth G Hill, Brian P Hobbs, Phyllis Pettit Nassi, Virgil H Simons, Chris H Takimoto

Get full text